FAM
RNAM

Fred Alger Management’s Avidity Biosciences RNAM Stock Holding History

Fred Alger Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,565
Closed -$286K – 505
2025
Q3 		$286K Buy
+6,565
New +$265K ﹤0.01% 426
2024
Q4 		– Sell
-17,320
Closed -$796K – 462
2024
Q3 		$796K Buy
17,320
+1,695
+11% +$73.6K ﹤0.01% 356
2024
Q2 		$638K Buy
+15,625
New +$448K ﹤0.01% 368
2023
Q3 		– Sell
-131,649
Closed -$1.46M – 523
2023
Q2 		$1.46M Sell
131,649
-26,244
-17% -$329K 0.01% 358
2023
Q1 		$2.42M Sell
157,893
-18,256
-10% -$402K 0.01% 321
2022
Q4 		$3.91M Buy
+176,149
New +$2.63M 0.02% 284
2022
Q1 		– Sell
-107,326
Closed -$2.55M – 549
2021
Q4 		$2.55M Buy
107,326
+12,521
+13% +$299K 0.01% 347
2021
Q3 		$2.33M Buy
+94,805
New +$2.06M 0.01% 341
2020
Q4 		– Sell
-16,243
Closed -$457K – 501
2020
Q3 		$457K Sell
16,243
-3,757
-19% -$109K ﹤0.01% 382
2020
Q2 		$565K Buy
+20,000
New +$577K ﹤0.01% 391

Other funds holding RNAM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fred Alger Management's RNAM Position: Q4 2025 in Review

Fred Alger Management sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 6,565 shares — an estimated $286K sold.

Fred Alger Management first reported a position in RNAM in Q2 2020 and held it in 10 quarters. The position peaked at $3.91M in Q4 2022. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

  • Fred Alger Management reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
  • Fred Alger Management sold 6,565 Avidity Biosciences shares in Q4 2025, an estimated $286K.
  • Fred Alger Management first reported a position in Avidity Biosciences in Q2 2020 and held it in 10 quarters.
  • Fred Alger Management's Avidity Biosciences position peaked at $3.91M in Q4 2022.
  • 343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Fred Alger Management's 13F filing for Q4 2025, filed 17 Feb 2026.